Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease

Victor R. Gordeuk, Andrew Campbell, Sohail Rana, Mehdi Nouraie, Xiaomei Niu, Caterina P. Minniti, Craig Sable, Deepika Darbari, Niti Dham, Onyinye Onyekwere, Tatiana Ammosova, Sergei Nekhai, Gregory J. Kato, Mark T. Gladwin, Oswaldo L. Castro

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Hydroxyurea and higher hemoglobin F improve the clinical course and survival in sickle cell disease, but their roles in protecting from pulmonary hypertension are not clear. We studied 399 children and adolescents with sickle cell disease at steady state; 38% were being treated with hydroxyurea. Patients on hydroxyurea had higher hemoglobin concentration and lower values for a hemolytic component derived from 4 markers of hemolysis (P ≤ .002) but no difference in tricuspid regurgitation velocity compared with those not receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) levels. Hemoglobin F correlated positively with erythropoietin even after adjustment for hemoglobin concentration (P < .001). Greater hemoglobin F and erythropoietin each independently predicted higher regurgitation velocity in addition to the hemolytic component (P ≤ .023). In conclusion, increase in hemoglobin F in sickle cell disease may be associated with relatively lower tissue oxygen delivery as reflected in higher erythropoietin concentration. Greater levels of erythropoietin or hemoglobin F were independently associated with higher tricuspid regurgitation velocity after adjustment for degree of hemolysis, suggesting an independent relationship of hypoxia with higher systolic pulmonary artery pressure. The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert countervailing influences on pulmonary blood pressure in sickle cell disease.

Original languageEnglish (US)
Pages (from-to)4639-4644
Number of pages6
JournalBlood
Volume114
Issue number21
DOIs
StatePublished - Nov 19 2009
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Tricuspid Valve Insufficiency
Hydroxyurea
Sickle Cell Anemia
Erythropoietin
Hemolysis
Therapeutics
Blood pressure
Pulmonary Hypertension
Pulmonary Artery
Hemoglobins
Tissue
Oxygen
Blood Pressure
Pressure
Lung
Survival

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. / Gordeuk, Victor R.; Campbell, Andrew; Rana, Sohail; Nouraie, Mehdi; Niu, Xiaomei; Minniti, Caterina P.; Sable, Craig; Darbari, Deepika; Dham, Niti; Onyekwere, Onyinye; Ammosova, Tatiana; Nekhai, Sergei; Kato, Gregory J.; Gladwin, Mark T.; Castro, Oswaldo L.

In: Blood, Vol. 114, No. 21, 19.11.2009, p. 4639-4644.

Research output: Contribution to journalArticle

Gordeuk, VR, Campbell, A, Rana, S, Nouraie, M, Niu, X, Minniti, CP, Sable, C, Darbari, D, Dham, N, Onyekwere, O, Ammosova, T, Nekhai, S, Kato, GJ, Gladwin, MT & Castro, OL 2009, 'Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease', Blood, vol. 114, no. 21, pp. 4639-4644. https://doi.org/10.1182/blood-2009-04-218040
Gordeuk, Victor R. ; Campbell, Andrew ; Rana, Sohail ; Nouraie, Mehdi ; Niu, Xiaomei ; Minniti, Caterina P. ; Sable, Craig ; Darbari, Deepika ; Dham, Niti ; Onyekwere, Onyinye ; Ammosova, Tatiana ; Nekhai, Sergei ; Kato, Gregory J. ; Gladwin, Mark T. ; Castro, Oswaldo L. / Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. In: Blood. 2009 ; Vol. 114, No. 21. pp. 4639-4644.
@article{88280b1cbc9f48c389a02a343e2207ec,
title = "Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease",
abstract = "Hydroxyurea and higher hemoglobin F improve the clinical course and survival in sickle cell disease, but their roles in protecting from pulmonary hypertension are not clear. We studied 399 children and adolescents with sickle cell disease at steady state; 38{\%} were being treated with hydroxyurea. Patients on hydroxyurea had higher hemoglobin concentration and lower values for a hemolytic component derived from 4 markers of hemolysis (P ≤ .002) but no difference in tricuspid regurgitation velocity compared with those not receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) levels. Hemoglobin F correlated positively with erythropoietin even after adjustment for hemoglobin concentration (P < .001). Greater hemoglobin F and erythropoietin each independently predicted higher regurgitation velocity in addition to the hemolytic component (P ≤ .023). In conclusion, increase in hemoglobin F in sickle cell disease may be associated with relatively lower tissue oxygen delivery as reflected in higher erythropoietin concentration. Greater levels of erythropoietin or hemoglobin F were independently associated with higher tricuspid regurgitation velocity after adjustment for degree of hemolysis, suggesting an independent relationship of hypoxia with higher systolic pulmonary artery pressure. The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert countervailing influences on pulmonary blood pressure in sickle cell disease.",
author = "Gordeuk, {Victor R.} and Andrew Campbell and Sohail Rana and Mehdi Nouraie and Xiaomei Niu and Minniti, {Caterina P.} and Craig Sable and Deepika Darbari and Niti Dham and Onyinye Onyekwere and Tatiana Ammosova and Sergei Nekhai and Kato, {Gregory J.} and Gladwin, {Mark T.} and Castro, {Oswaldo L.}",
year = "2009",
month = "11",
day = "19",
doi = "10.1182/blood-2009-04-218040",
language = "English (US)",
volume = "114",
pages = "4639--4644",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease

AU - Gordeuk, Victor R.

AU - Campbell, Andrew

AU - Rana, Sohail

AU - Nouraie, Mehdi

AU - Niu, Xiaomei

AU - Minniti, Caterina P.

AU - Sable, Craig

AU - Darbari, Deepika

AU - Dham, Niti

AU - Onyekwere, Onyinye

AU - Ammosova, Tatiana

AU - Nekhai, Sergei

AU - Kato, Gregory J.

AU - Gladwin, Mark T.

AU - Castro, Oswaldo L.

PY - 2009/11/19

Y1 - 2009/11/19

N2 - Hydroxyurea and higher hemoglobin F improve the clinical course and survival in sickle cell disease, but their roles in protecting from pulmonary hypertension are not clear. We studied 399 children and adolescents with sickle cell disease at steady state; 38% were being treated with hydroxyurea. Patients on hydroxyurea had higher hemoglobin concentration and lower values for a hemolytic component derived from 4 markers of hemolysis (P ≤ .002) but no difference in tricuspid regurgitation velocity compared with those not receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) levels. Hemoglobin F correlated positively with erythropoietin even after adjustment for hemoglobin concentration (P < .001). Greater hemoglobin F and erythropoietin each independently predicted higher regurgitation velocity in addition to the hemolytic component (P ≤ .023). In conclusion, increase in hemoglobin F in sickle cell disease may be associated with relatively lower tissue oxygen delivery as reflected in higher erythropoietin concentration. Greater levels of erythropoietin or hemoglobin F were independently associated with higher tricuspid regurgitation velocity after adjustment for degree of hemolysis, suggesting an independent relationship of hypoxia with higher systolic pulmonary artery pressure. The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert countervailing influences on pulmonary blood pressure in sickle cell disease.

AB - Hydroxyurea and higher hemoglobin F improve the clinical course and survival in sickle cell disease, but their roles in protecting from pulmonary hypertension are not clear. We studied 399 children and adolescents with sickle cell disease at steady state; 38% were being treated with hydroxyurea. Patients on hydroxyurea had higher hemoglobin concentration and lower values for a hemolytic component derived from 4 markers of hemolysis (P ≤ .002) but no difference in tricuspid regurgitation velocity compared with those not receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) levels. Hemoglobin F correlated positively with erythropoietin even after adjustment for hemoglobin concentration (P < .001). Greater hemoglobin F and erythropoietin each independently predicted higher regurgitation velocity in addition to the hemolytic component (P ≤ .023). In conclusion, increase in hemoglobin F in sickle cell disease may be associated with relatively lower tissue oxygen delivery as reflected in higher erythropoietin concentration. Greater levels of erythropoietin or hemoglobin F were independently associated with higher tricuspid regurgitation velocity after adjustment for degree of hemolysis, suggesting an independent relationship of hypoxia with higher systolic pulmonary artery pressure. The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert countervailing influences on pulmonary blood pressure in sickle cell disease.

UR - http://www.scopus.com/inward/record.url?scp=73949092418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949092418&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-04-218040

DO - 10.1182/blood-2009-04-218040

M3 - Article

C2 - 19724057

AN - SCOPUS:73949092418

VL - 114

SP - 4639

EP - 4644

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -